Cargando…

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials

AIMS/INTRODUCTION: This meta‐analysis aimed to evaluate the efficacy and safety/tolerability of imeglimin, a novel oral antihyperglycemic agent, administered as monotherapy and adjunctive therapy in patients with type 2 diabetes mellitus. MATERIALS AND METHODS: Parallel‐group randomized controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagi, Katsuhiko, Nitta, Masahiro, Watada, Hirotaka, Kaku, Kohei, Ueki, Kohjiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583642/ https://www.ncbi.nlm.nih.gov/pubmed/37610062 http://dx.doi.org/10.1111/jdi.14070

Ejemplares similares

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
por: Reilhac, Caroline, et al.
Publicado: (2022)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis
por: Kishimoto, Taishiro, et al.
Publicado: (2023)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

A Response to Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Uchida, Taisuke, et al.
Publicado: (2023)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
por: Komatsu, Mitsuhisa, et al.
Publicado: (2021)

Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
por: Sanada, Junpei, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus
por: Sasako, Takayoshi, et al.
Publicado: (2023)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis
por: Kadakia, Aditi, et al.
Publicado: (2021)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2011)

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
por: Terauchi, Yasuo, et al.
Publicado: (2017)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan
por: Kaku, Kohei, et al.
Publicado: (2015)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2012)

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Efficacy and tolerability of lurasidone in schizophrenia: A systematic review and meta-analysis of short-term, randomized, placebo controlled trials
por: Hagi, K., et al.
Publicado: (2021)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

Efficacy and safety of the G protein‐coupled receptor 119 agonist DS‐8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo‐controlled study
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes
por: Yamagishi, Hirofumi, et al.
Publicado: (2023)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ji56cjav15hfhu9spdia2bpq3